Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 2-3 , January 2004

Radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin): The role of the nuclear medicine physician

  • Peter S. Conti

      Affiliations

    • Departments of Radiology, Clinical Pharmacy, and Biomedical Engineering, University of Southern California, Los Angeles, CA, USA
    • *Address reprint requests to Peter S. Conti, MD, PhD, 1510 San Pablo St, Suite 350, Los Angeles, CA 90033, USA
    • 1Dr Conti serves as a consultant and member of the speakers’ bureau for Biogen Idec Inc.

References 

  1. Potamianos S, Varvarigou AD, Archimandritis SC. Radioimmunoscintigraphy and radioimmunotherapy in cancer: Principles and application. Anticancer Res. 2000;20:925–948
  2. Zevalin (ibritumomab tiuxetan) prescribing information. San Diego, CA: IDEC Pharmaceuticals Corporation,; 2002;
  3. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol. 1999;11:375–380
  4. Anderson KC, Bates MP, Slaughenhoupt BL, et al.  Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood. 1984;63:1424–1433
  5. Wagner HN, Wiseman GA, Marcus CS, et al.  Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267–272

PII: S0001-2998(03)00080-1

doi: 10.1053/j.semnuclmed.2003.11.003

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 2-3 , January 2004

Article Tools